ICU Medical, Inc.
General ticker "ICUI" information:
- Sector: Health Care
- Industry: Medical - Instruments & Supplies
- Capitalization: $3.4B (TTM average)
ICU Medical, Inc. follows the US Stock Market performance with the rate: 11.6%.
Estimated limits based on current volatility of 1.9%: low 150.31$, high 156.19$
Factors to consider:
- Total employees count: 15000 (+7.1%) as of 2024
- US accounted for 64.3% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Market competition, Economic downturns and volatility, Cybersecurity threats, Integration failure, Management distraction
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [123.33$, 197.88$]
- 2025-12-31 to 2026-12-31 estimated range: [133.81$, 212.34$]
Financial Metrics affecting the ICUI estimates:
- Negative: with PPE of 24.9 at the end of fiscal year the price was high
- Positive: -5.02 < Operating profit margin, % of 1.80
- Positive: 42.53 < Shareholder equity ratio, % of 46.75 <= 64.17
- Positive: -4.41 < Investing cash flow per share per price, % of -2.35
- Positive: Inventory ratio change, % of -4.20 <= -0.76
- Positive: -3.57 < Return on assets ratio (scaled to [-100,100]) of -2.72
- Positive: -0.04 < Industry operating cash flow per share per price (median), % of 1.00
- Positive: 0.04 < Operating cash flow per share per price, % of 5.39
Short-term ICUI quotes
Long-term ICUI plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $2,280.00MM | $2,259.13MM | $2,382.05MM |
| Operating Expenses | $2,322.89MM | $2,236.30MM | $2,339.08MM |
| Operating Income | $-42.90MM | $22.82MM | $42.96MM |
| Non-Operating Income | $-71.51MM | $-101.12MM | $-108.98MM |
| Interest Expense | $66.38MM | $95.22MM | $95.75MM |
| R&D Expense | $92.98MM | $85.34MM | $88.61MM |
| Income(Loss) | $-114.41MM | $-78.30MM | $-66.01MM |
| Taxes | $-40.12MM | $-48.64MM | $51.68MM |
| Profit(Loss)* | $-74.29MM | $-29.66MM | $-117.69MM |
| Stockholders Equity | $2,089.93MM | $2,123.41MM | $1,965.23MM |
| Inventory | $696.01MM | $709.36MM | $584.68MM |
| Assets | $4,515.64MM | $4,378.44MM | $4,203.93MM |
| Operating Cash Flow | $-62.13MM | $166.20MM | $204.03MM |
| Capital expenditure | $99.33MM | $93.67MM | $79.37MM |
| Investing Cash Flow | $-1,909.47MM | $-87.95MM | $-88.96MM |
| Financing Cash Flow | $1,637.03MM | $-35.98MM | $-55.80MM |
| Earnings Per Share** | $-3.11 | $-1.23 | $-4.83 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.